Technology
Developing a better ACE2 variant to address multiple indications aggressively and effectively
Executive Summary
Moving our molecules to clinical development in multiple indications
News
Bioengineered Protein May Prevent COVID Infections and Improve Survival Northwestern Medicine (May 9, 2023)
Study Shows Cell Membrane-Bound Enzyme is Essential for COVID-19 Infection Northwestern Medicine (May 26, 2022)
Angiotensin Therapeutics Inc. announces publication of a study using a soluble ACE2 protein designed for COVID-19 Press Release (May 8, 2022)
A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection Journal of the American Society of Nephrology (July 2022)
Can you spot the fake receptor? The coronavirus can’t either. MIT Technology Review (August 27, 2021)
Podcast: Kidneys, COVID-19 and ACE2 Connection with Daniel Batlle, MD Northwestern University (March 17, 2021)
Fooling coronavirus with new decoy protein renders it impotent Northwestern University (March 29, 2021)
Novel protein construct prevents lethal COVID-19 in mice News Medical (March 16, 2021)
Angiotensin Therapeutics Inc. Announces Publication of a Novel Approach to COVID 19 Therapy. Press Release. (February 3, 2021)
Angiotensin Therapeutics Inc. Announces Publication of a Novel Approach to COVID 19 Therapy. BioSpace. (February 4, 2021)
New Protein Neutralizes COVID in Tiny Human Kidney. Northwestern University. (February 2, 2021)
Latest Publications
Intranasal soluble ACE2 improves survival and prevents brain SARS-CoV-2 infection. Luise Hassler, Jan Wysocki, Jared T Ahrendsen, Minghao Ye, Ian Gelarden, Vlad Nicolaescu, Anastasia Tomatsidou, Haley Gula, Cosimo Cianfarini, Peter Foster, Nigar Khurram, Benjamin D Singer, Glenn Randall, Dominique Missiakas, Jack Henkin, and Daniel Batlle. Life Science Alliance. April 2023; 6(7):e202301969. DOI.
A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. Jan Wysocki, Minghao Ye, Luise Hassler, Ashwani Kumar Gupta, Yuguo Wang, Vlad Nicoleascu, Glenn Randall, Jason A. Wertheim and Daniel Batlle. JASN February 2021, ASN.2020101537; DOI.
Davidson AM, Wysocki J, Batlle D. Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. Hypertension. 2020 Nov;76(5):1339-1349. doi: 10.1161/HYPERTENSIONAHA.120.
Wysocki J, Schulze A, Batlle D. Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System. Biomolecules. 2019 Dec 17;9(12). doi: 10.3390/biom9120886. PubMed PMID: 31861139; PubMed Central PMCID: PMC6995632.
Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?. Clin Sci (Lond). 2020 Mar 13;134(5):543-545. doi: 10.1042/CS20200163. PubMed PMID: 32167153.
Marquez A, Wysocki J, Pandit J, Batlle D. An update on ACE2 amplification and its therapeutic potential. Acta Physiol (Oxf). 2020 May 29;:e13513. doi: 10.1111/apha.13513. [Epub ahead of print] Review. PubMed PMID: 32469114; PubMed Central PMCID: PMC7267104.
Wysocki J, Lores E, Ye M, Soler MJ, Batlle D. Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. J Am Soc Nephrol. 2020 Sep;31(9):1941-1943. doi: 10.1681/ASN.2020050667. Epub 2020 Jul 15. PubMed PMID: 32669323; PubMed Central PMCID: PMC7461678.
Contact Us
Fill out the form below with any questions you may have and we’ll get back to you soon with a response.
Please note AngioTX is not hiring.
Please note that AngioTX is not hiring.